babak Pezeshki

babak Pezeshki


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
ZEZarenezhad Elham
Zarenezhad Elham
HAHussein Thaer Abdulabbas
Hussein Thaer Abdulabbas
MMMahrokh Marzi
Mahrokh Marzi
EGEsraa Ghazy
Esraa Ghazy
MEMohammad Ekrahi
Mohammad Ekrahi
Amira Awad MoawadAmira Awad Moawad
Amira Awad Moawad
Methicillin-resistant Staphylococcus aureus (MRSA) has evolved vast antibiotic resistance. These strains contain numerous virulence factors facilitating the development of severe infections. Considering the costs, side effects, and time duration needed for the synthesis of novel drugs, seeking efficient alternative approaches for the eradication of drug-resistant bacterial agents seems to be an unmet requirement. Nickel nanoparticles (NiNPs) have been applied as prognostic and therapeutic cheap agents to various aspects of biomedical sciences. Their antibacterial effects are exerted via the disruption of the cell membrane, the deformation of proteins, and the inhibition of DNA replication. NiNPs proper traits include high-level chemical stability and binding affinity, ferromagnetic properties, ecofriendliness, and cost-effectiveness. They have outlined pleomorphic and cubic structures. The combined application of NiNPs with CuO, ZnO, and CdO has enhanced their anti-MRSA effects. The NiNPs at an approximate size of around 50 nm have exerted efficient anti-MRSA effects, particularly at higher concentrations. NiNPs have conferred higher antibacterial effects against MRSA than other nosocomial bacterial pathogens. The application of green synthesis and low-cost materials such as albumin and chitosan enhance the efficacy of NPs for therapeutic purposes.

11 July 2023 in Journal of Health, Population and Nutrition
Verified
Journal Article
Open access
PDF file
MSMehdi Sharafi
Mehdi Sharafi
ZAZahra Amiri
Zahra Amiri
BPbabak Pezeshki
babak Pezeshki
MMMohammad Ali Mohsenpour
Mohammad Ali Mohsenpour
MEMohammad Hassan Eftekhari
Mohammad Hassan Eftekhari
ZMZahra Mastaneh
Zahra Mastaneh
Background: The triglyceride glucose (TyG) and triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-c) are the indices that can predict the progression of pre-diabetes to type 2 diabetes mellitus (T2DM). This study aimed to examine the relationship between TyG and TG/HDL-c indices with the incidence of T2DM in pre-diabetes patients. Methods: A total of 758 pre-diabetic patients aged 35–70 years who were enrolled in a prospective Fasa Persian Adult Cohort were followed up for 60 months. TyG and TG/HDL-C indices were obtained at baseline data and divided into quartiles. The 5-year cumulative incidence of T2DM was analyzed by Cox proportional hazards regression analysis while controlling for baseline covariates. Results: During 5 years of follow-up, there were 95 incident cases of T2DM, with an overall incidence rate of 12.53%. After adjusting for age, sex, smoking, marital status, socioeconomic status, body mass index, waist circumference, hip circumference, hypertension, total cholesterol, and dyslipidemia, the multivariate-adjusted hazard ratios (HRs) demonstrated that patients with the highest TyG and TG/HDL-C indices quartile were at higher risk of T2DM (HR = 4.42, 95%CI 1.75–11.21) and (HR = 2.15, 95%CI 1.04–4.47), respectively, compared to participants in the lowest quartile. As the quantiles of these indices increase, the HR value shows a significant increment (P < 0.05). Conclusion: The results of our study showed that the TyG and TG/HDL-C indices can be important independent predictors for the progression of pre-diabetes to T2DM. Therefore, controlling the components of these indicators in pre-diabetes patients can prevent developing T2DM or delay its occurrence.

19 July 2018 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MAMajid Akrami
Majid Akrami
ASAfrooz Sepahdar
Afrooz Sepahdar
PAPeyman Arasteh
Peyman Arasteh
STSedigheh Tahmasebi
Sedigheh Tahmasebi
VZVahid Zangouri
Vahid Zangouri
ATAbdolrasoul Talei
Abdolrasoul Talei
In here, we evaluated pattern of metastasis and cross-compared clinicopathological features between different age groups with breast cancer (BC). This study was conducted in the Shiraz Breast Cancer Registry (largest BC registry in Iran). Patients were classified as < 30 years old (group 1), 30–60 years old (group 2), and > 60 years old (group 3). The three age groups were compared regarding clinical and baseline characteristics. Overall, 564 individuals entered group 1, 4519 group 2, and 670 group 3. Group 1 had lower rates of tumor necrosis (p < 0.001), higher lymphatic or vascular invasion (p = 0.002), estrogen receptor-negative individuals, and HER2-positive individuals (p ≤ 0.001). Younger groups had more stage 3 BC (31.1, 25.6, and 19.7% for groups 1, 2, and 3, respectively) (p = 0.016), grade 3 BC (27.4, 20.6, and 16.5% for groups 1, 2, and 3, respectively) (p = 0.001), and grade 3 nucleus (43.1, 34.5, and 27.6% for groups 1, 2, and 3, respectively) (p < 0.001). Group 1 had higher rates of regional metastasis (4.7 vs. 1.5 and 2.1% for groups 2 and 3, respectively). Younger individuals had higher rates of brain metastasis (13.3, 5.4, and 1.1% for groups 1, 2, and 3, respectively). Moreover, those > 60 years old had more lung metastasis (33 vs. 12.6 and 6.7% for groups 2 and 1, respectively) (p < 0.001). Younger groups had more < 5-year recurrence (16.3, 11.7, and 8.9%, for groups 1, 2, and 3, respectively) (p = 0.023). Pattern and site of recurrence changes according to age in BC. This brings up the question whether age is an independent predictor of organ of metastasis or is site of metastasis the result of other clinicopathological determinants which differ between age groups.

15 December 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
SBSina Bazmi
Sina Bazmi
MFMohammadreza Fardaei
Mohammadreza Fardaei
RHReza Homayounfar
Reza Homayounfar
MKMaryam Kazemi
Maryam Kazemi
BPbabak Pezeshki
babak Pezeshki
MFMojtaba Farjam
Mojtaba Farjam
The updated metabolic dysfunction-associated steatotic liver disease (MASLD) framework highlights the systemic impact of hepatic steatosis, including kidne

1 September 2021 in Nursing and Midwifery Journal
Verified
Journal Article
Open access
PDF file
BPbabak Pezeshki
babak Pezeshki
MBMostafa Bijani
Mostafa Bijani
ADAzizollah Dehghan
Azizollah Dehghan
ZSZahra Salehi
Zahra Salehi
Background & Aims: Diabetes Mellitus (DM) is the most common chronic disease in the world that is the major risk factor of fatal diseases such as myocardial infarction and stroke also the complication of DM is a common cause of disability. The most important treatment to control DM is insulin therapy; ...

25 July 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
HAHamid Aria
Hamid Aria
MAMahdieh Azizi
Mahdieh Azizi
SNShima Nazem
Shima Nazem
MBMaryam Bahmanyar
Maryam Bahmanyar
AMAli Moravej
Ali Moravej
YMYaser Mansouri
Yaser Mansouri
Cancer stem cells (CSCs) are one of the cell types that account for cancer heterogeneity. They arrest in the G0 phase and generate non-CSC progeny by self-renewing and pluripotency activity, resulting in tumor recurrence, metastasis, and chemoresistance. One CSC can stimulate tumor relapse and can re-grow a metastatic tumor. So, CSC is a promising target for eradicating tumors, and developing an anti-CSC method has become a top priority in cancer therapy. In recent years competing endogenous RNA (ceRNA) have emerged as an important class of post-transcriptional regulators that affect gene expression via competition for microRNA (miRNA) binding. Furthermore, aberrant ceRNA expression is associated with tumor progression. To overcome therapeutic resistance due to CSCs, we need to improve our existing understanding of the mechanisms by which ceRNAs are implicated in CSC-related relapse. Thus, this review was designed in order to discuss the role of ceRNAs in CSCs function. We reviewed the role of ceRNAs in acquiring CSCs characteristics in the form of different pathways including Rho GTPase/F-actin_ Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) (Hippo), Wnt/β-catenin pathway, transforming growth factor (TGF)-b–urothelial carcinoma-associated 1 (UCA1)–Slug pathway, etc. Finally, considering the comprehensive impacts of the ceRNA network on different pathways, a treatment strategy driving the ceRNA network might be effective. Targeting ceRNAs may open the path for new cancer therapeutic targets and can be used in clinical research.